After planned administration, the number of tumor-infiltrating CD4+ and CD8+ T cells increased from 22 to 30.8% and from 4.8 to 8.6% respectively in diosgenin-treated cohort, while that increased to 27.6 and 17.5% respectively in combined administration cohort (Fig. 5d). Here, CD4 is linked to neoplasm.